Oculis Holding AG (NASDAQ:OCS) Short Interest Up 105.6% in December

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 101,167 shares, an increase of 105.6% from the November 30th total of 49,197 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 95,845 shares, the short-interest ratio is currently 1.1 days. Based on an average daily trading volume, of 95,845 shares, the short-interest ratio is currently 1.1 days. Currently, 0.2% of the shares of the company are sold short.

Oculis Trading Down 1.9%

NASDAQ OCS traded down $0.39 during mid-day trading on Monday, reaching $20.11. 16,094 shares of the stock were exchanged, compared to its average volume of 57,952. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. Oculis has a 1-year low of $14.00 and a 1-year high of $23.08. The business’s fifty day simple moving average is $20.00 and its 200 day simple moving average is $18.89. The stock has a market capitalization of $1.05 billion, a PE ratio of -7.98 and a beta of 0.32.

Oculis (NASDAQ:OCS) last posted its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. On average, research analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OCS has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. HC Wainwright upped their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Stifel Nicolaus raised their price target on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Oculis in a research note on Tuesday, November 11th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and an average target price of $41.50.

Hedge Funds Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. bought a new stake in shares of Oculis in the 1st quarter worth $2,499,000. Woodline Partners LP raised its position in Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares in the last quarter. Marshall Wace LLP acquired a new stake in Oculis in the 2nd quarter valued at about $393,000. Bosun Asset Management LLC bought a new position in shares of Oculis during the 2nd quarter valued at about $378,000. Finally, Compagnie Lombard Odier SCmA grew its stake in shares of Oculis by 11.5% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after purchasing an additional 10,000 shares during the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.